LEADER 02276nam 2200601 450 001 9910460763903321 005 20200520144314.0 010 $a978-918-269-4 035 $a(CKB)3710000000431510 035 $a(EBL)2068772 035 $a(SSID)ssj0001530865 035 $a(PQKBManifestationID)12622297 035 $a(PQKBTitleCode)TC0001530865 035 $a(PQKBWorkID)11532525 035 $a(PQKB)10399480 035 $a(MiAaPQ)EBC2068772 035 $a(OCoLC)913500510 035 $a(MdBmJHUP)muse48301 035 $a(PPN)228029317 035 $a(Au-PeEL)EBL2068772 035 $a(CaPaEBR)ebr11066733 035 $a(CaONFJC)MIL802365 035 $a(EXLCZ)993710000000431510 100 $a20150629h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aKing of the jungle $efiction /$fBizuum Yadok 210 1$aIbadan, Oyo State, Nigeria :$cKraft Books Limited,$d2014. 210 4$dİ2014 215 $a1 online resource (273 p.) 225 0 $aKraftgriots 300 $a"Kraftgriots (A literary imprint of Kraft Books Limited)"--Title page verso. 311 $a978-918-209-0 327 $aCover; Title page; Copyright page; Dedication; Acknowledgement; One; Two; Three; Four; Five; Six; Seven; Eight; Nine; Ten; Eleven; Twelve; Thirteen; Fourteen; Fifteen; Sixteen; Seventeen; Eighteen; Nineteen; Twenty; Epilogue; Author's Note; Back cover 330 $aIn King of the Jungle, the bouts of ethno-religious violence in Jos are fused with the heartbreaking story of two brothers who go through life unaware of each other's existence. Carefully crafted with local colour which evokes memories of pre-2001 Jos, Bizuum Yadok's first novel weaves humour, urban realism, tragedy and redemption. 410 0$aFiction (Ibadan, Nigeria) 606 $aBrothers$vFiction 606 $aCity and town life in literature 608 $aElectronic books. 615 0$aBrothers 615 0$aCity and town life in literature. 676 $a813.54 700 $aYadok$b Bizuum$01045431 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460763903321 996 $aKing of the jungle$92471716 997 $aUNINA LEADER 04162nam 2200697Ia 450 001 9910971069003321 005 20251017110118.0 010 $a9786610567409 010 $a9780309180900 010 $a0309180902 010 $a9781280567407 010 $a1280567406 010 $a9780309660938 010 $a0309660939 035 $a(CKB)1000000000466038 035 $a(EBL)3378125 035 $a(SSID)ssj0000217108 035 $a(PQKBManifestationID)11209826 035 $a(PQKBTitleCode)TC0000217108 035 $a(PQKBWorkID)10202206 035 $a(PQKB)10182084 035 $a(Au-PeEL)EBL3378125 035 $a(CaPaEBR)ebr10141205 035 $a(CaONFJC)MIL56740 035 $a(OCoLC)923276964 035 $a(MiAaPQ)EBC3378125 035 $a(Perlego)4737056 035 $a(DNLM)1309055 035 $a(BIP)13526032 035 $a(EXLCZ)991000000000466038 100 $a20060414d2006 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aOvercoming challenges to develop countermeasures against aerosolized bioterrorism agents $eappropriate use of animal models /$fCommittee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies 205 $a1st ed. 210 $aWashington D.C. $cThe National Academies Press$dc2006 215 $a1 online resource (88 p.) 300 $aDescription based upon print version of record. 311 08$a9780309102117 311 08$a0309102111 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Preface""; ""Contents""; ""Glossary""; ""Summary""; ""1 Introduction""; ""2 Selection or Development of an Animal Model""; ""3 Generation and Characterization of Aerosolized Agents""; ""4 Dosimetry Considerations""; ""5 Experimental Design""; ""6 Resource Issues""; ""References""; ""About the Authors""; ""Appendix A: Public Workshop Agenda, and Biographical Information about the Speakers,"" 330 $aThe National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies--including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)--be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies. 606 $aBioterrorism$xResearch 606 $aChemical warfare 615 0$aBioterrorism$xResearch. 615 0$aChemical warfare. 676 $a363.325 712 02$aNational Research Council (U.S.).$bCommittee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents. 712 02$aNational Research Council (U.S.).$bBoard on Life Sciences. 712 02$aInstitute for Laboratory Animal Research (U.S.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910971069003321 996 $aOvercoming challenges to develop countermeasures against aerosolized bioterrorism agents$94358238 997 $aUNINA